GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Institutional Ownership

Shanghai Henlius Biotech (HKSE:02696) Institutional Ownership : 0.72% (As of May. 08, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Shanghai Henlius Biotech's institutional ownership is 0.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Shanghai Henlius Biotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Shanghai Henlius Biotech's Float Percentage Of Total Shares Outstanding is 0.00%.


Shanghai Henlius Biotech Institutional Ownership Historical Data

The historical data trend for Shanghai Henlius Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Institutional Ownership Chart

Shanghai Henlius Biotech Historical Data

The historical data trend for Shanghai Henlius Biotech can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 0.41 0.64 0.63 0.63 0.63 0.74 0.74 0.70 0.72 0.72

Shanghai Henlius Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Ubs Group Ag
Golden Valley Value Select Master Fund 2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Lvc Sg Management Pte. Ltd. 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lin Lijun 2201 Interest of corporation controlled by you
Qatar Investment Authority 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines